|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000163697 |
Summary for APBB2 |
Gene summary |
| Gene information | Ensembl ID | ENSG00000163697 | Gene symbol | APBB2 |
| Gene name | amyloid beta precursor protein binding family B member 2 | |
| HGNC | 582 | |
| Entrez ID | 323 | |
| Gene type | protein_coding | |
| Synonyms | APBB2|FE65L|FE65L1|MGC35575 | |
| UniProtAcc | Q92870 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for APBB2 |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| APBB2 | 2.01e+03 | -1.05e+00 | 1.18e-01 | -8.88e+00 | 6.90e-19 | 7.61e-18 | LUAD |
| APBB2 | 2.29e+03 | 1.27e+00 | 2.04e-01 | 6.22e+00 | 4.90e-10 | 1.39e-08 | HNSC |
Top |
Sex-biased somatic mutation for APBB2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for APBB2 |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25333257 | chr4:41215786 | CGI:chr4:41216523-41216751 | promoter,gene body | 5.64e-01 | 4.27e-01 | 2.40e+00 | 1.63e-02 | 3.23e-02 | 1.37e-01 |
| BRCA | cg27434086 | chr4:41216065 | CGI:chr4:41216523-41216751 | promoter,gene body | 4.19e-01 | 2.98e-01 | 2.63e+00 | 8.61e-03 | 2.53e-02 | 1.21e-01 |
| DLBC | cg27434086 | chr4:41216065 | CGI:chr4:41216523-41216751 | promoter,gene body | 5.87e-01 | 7.05e-01 | -2.07e+00 | 3.85e-02 | 4.62e-02 | -1.19e-01 |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg27434086 | chr4:41216065 | CGI:chr4:41216523-41216751 | promoter,gene body | 3.17e-01 | 4.21e-01 | -4.40e+00 | 1.10e-05 | 2.97e-05 | -1.04e-01 |
| ESCA | cg24541457 | chr4:41215700 | CGI:chr4:41216523-41216751 | promoter,gene body | 8.72e-01 | 7.37e-01 | 2.37e+00 | 1.77e-02 | 3.94e-02 | 1.34e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25333257 | chr4:41215786 | CGI:chr4:41216523-41216751 | promoter,gene body | 5.64e-01 | 7.68e-01 | -1.14e+01 | 3.09e-30 | 4.63e-29 | -2.03e-01 |
| HNSC | cg27434086 | chr4:41216065 | CGI:chr4:41216523-41216751 | promoter,gene body | 4.97e-01 | 3.68e-01 | 2.32e+00 | 2.04e-02 | 2.79e-02 | 1.29e-01 |
Top |
Exon skipping events with PSI in TCGA for APBB2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Landscape of exon skipping events across multiple cancer types. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| ESCA | exon_skip_429286 | 6.93e-01 | 8.12e-01 | -2.61e+00 | 9.13e-03 | 2.34e-02 | -1.20e-01 |
| KICH | exon_skip_429274 | 6.62e-01 | 5.11e-01 | 3.18e+00 | 1.50e-03 | 6.45e-03 | 1.51e-01 |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| THCA | exon_skip_429274 | 8.13e-01 | 6.91e-01 | 6.04e+00 | 1.55e-09 | 4.41e-08 | 1.22e-01 |
| STAD | exon_skip_429286 | 6.75e-01 | 8.02e-01 | -2.76e+00 | 5.73e-03 | 1.85e-02 | -1.27e-01 |
Top |
RNA A-to-I editing events in TCGA for APBB2 |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for APBB2 |
TFs related to APBB2.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BLCA | FOXA1 | APBB2 | 3.06e+00 | 3.08e-03 | 4.19e+00 | 9.85e-01 | Female-biased |
| BLCA | FOXA2 | APBB2 | 3.41e+00 | 8.23e-03 | 4.30e+00 | 9.81e-01 | Female-biased |
| BLCA | FOXA3 | APBB2 | 3.16e+00 | 3.71e-03 | 4.26e+00 | 9.85e-01 | Female-biased |
| BLCA | FOXB1 | APBB2 | 3.07e+00 | 4.16e-03 | 4.13e+00 | 9.82e-01 | Female-biased |
| BLCA | FOXD3 | APBB2 | 3.04e+00 | 4.24e-03 | 4.09e+00 | 9.81e-01 | Female-biased |
| BLCA | FOXG1 | APBB2 | 2.64e+00 | 1.24e-03 | 4.01e+00 | 9.82e-01 | Female-biased |
| BLCA | FOXL1 | APBB2 | 2.64e+00 | 1.21e-03 | 4.01e+00 | 9.82e-01 | Female-biased |
| BLCA | FOXP3 | APBB2 | 3.65e+00 | 9.71e-03 | 4.51e+00 | 9.83e-01 | Female-biased |
| BLCA | LHX3 | APBB2 | 3.35e+00 | 7.41e-03 | 4.27e+00 | 9.82e-01 | Female-biased |
| BLCA | LMX1B | APBB2 | 3.08e+00 | 3.39e-03 | 4.19e+00 | 9.84e-01 | Female-biased |
| BLCA | MEF2A | APBB2 | 2.87e+00 | 2.52e-03 | 4.05e+00 | 9.82e-01 | Female-biased |
| BLCA | SOX15 | APBB2 | 3.52e+00 | 9.45e-03 | 4.38e+00 | 9.81e-01 | Female-biased |
| BLCA | ZNF418 | APBB2 | 2.49e+00 | 1.49e-04 | 4.43e+00 | 9.92e-01 | Female-biased |
| BLCA | ZNF580 | APBB2 | 3.50e+00 | 9.82e-03 | 4.35e+00 | 9.80e-01 | Female-biased |
| BLCA | ZNF79 | APBB2 | 2.82e+00 | 9.44e-04 | 4.26e+00 | 9.88e-01 | Female-biased |
| BLCA | ZNF879 | APBB2 | 2.24e+00 | 3.13e-04 | 3.98e+00 | 9.82e-01 | Female-biased |
| LGG | ZBTB20 | APBB2 | 5.07e+00 | 9.84e-01 | 4.64e+00 | 1.31e-02 | Male-biased |
APBB2 related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for APBB2 |
RBPs related to ES in APBB2.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ESCA | MSI1 | exon_skip_429276 | 1.14e+01 | 1.27e-02 | 1.18e+01 | 9.87e-01 | Female-biased |
| THCA | MSI1 | exon_skip_429276 | 1.16e+01 | 1.49e-03 | 1.20e+01 | 9.98e-01 | Female-biased |
| THCA | RBM42 | exon_skip_429276 | 7.73e+00 | 2.00e-03 | 8.17e+00 | 9.90e-01 | Female-biased |
APBB2 related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1447367 | chr4:30846513:G:C | - | 0.137341853877842 | 0.0153481219215617 | SARC | Female-baised eQTL |
| rs1447369 | chr4:30837611:T:G | - | 0.13300094183336 | 0.0222576178017349 | SARC | Female-baised eQTL |
| rs1374656 | chr4:30835572:C:T | - | 0.130967881369774 | 0.0255295960834667 | SARC | Female-baised eQTL |
| rs1595192 | chr4:43114263:A:T | - | -0.13410933439255 | 0.00358356599446964 | LIHC | Female-baised eQTL |
| rs6447217 | chr4:43094277:G:T | - | -0.124000416335221 | 0.0105250863269332 | LIHC | Female-baised eQTL |
| rs76161958 | chr4:43098001:A:C | - | -0.124000416335221 | 0.0105250863269332 | LIHC | Female-baised eQTL |
| rs6447225 | chr4:43104776:T:C | - | -0.124000416335221 | 0.0105250863269332 | LIHC | Female-baised eQTL |
| rs7663681 | chr4:43107726:A:G | - | -0.124000416335221 | 0.0105250863269332 | LIHC | Female-baised eQTL |
| rs1545100 | chr4:43075579:T:A | - | -0.116929968731599 | 0.0297812718916401 | LIHC | Female-baised eQTL |
| rs6828092 | chr4:43077066:C:G | - | -0.116929968731599 | 0.0297812718916401 | LIHC | Female-baised eQTL |
| rs6447232 | chr4:43121658:T:C | - | -0.129507885370859 | 0.0338297336958374 | LIHC | Female-baised eQTL |
| rs6447235 | chr4:43122289:A:T | - | -0.129507885370859 | 0.0338297336958374 | LIHC | Female-baised eQTL |
| rs1436485 | chr4:43122693:A:G | - | -0.129507885370859 | 0.0338297336958374 | LIHC | Female-baised eQTL |
| rs6857381 | chr4:43109518:C:T | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs6853503 | chr4:43112048:A:T | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs6853539 | chr4:43112106:A:G | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs6824901 | chr4:43114658:T:G | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs6447229 | chr4:43114923:C:G | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs6850047 | chr4:43115561:C:A | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs6851235 | chr4:43116781:T:C | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs6846222 | chr4:43116846:A:G | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs1595194 | chr4:43118813:G:A | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs4446351 | chr4:43119842:C:G | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs6847169 | chr4:43120153:C:A | - | -0.122480743008776 | 0.0447204415188201 | LIHC | Female-baised eQTL |
| rs707723 | chr4:47840232:A:G | - | -0.111572676114157 | 0.0375085065104658 | STAD | Female-baised eQTL |
| rs920463 | chr4:47855669:C:T | - | -0.111572676114157 | 0.0375085065104658 | STAD | Female-baised eQTL |
| rs2352457 | chr4:47929984:T:C | - | -0.114338140262651 | 0.0383031810582731 | STAD | Female-baised eQTL |
| rs35025704 | chr4:47933228:G:A | - | -0.114338140262651 | 0.0383031810582731 | STAD | Female-baised eQTL |
| rs9291318 | chr4:47935710:G:A | - | -0.114338140262651 | 0.0383031810582731 | STAD | Female-baised eQTL |
| rs28656217 | chr4:42097407:T:C | - | 0.114698335923959 | 0.0412245456771392 | STAD | Female-baised eQTL |
| rs7659193 | chr4:42052863:A:G | - | 0.112277180336825 | 0.0429396491456461 | STAD | Female-baised eQTL |
| rs6813513 | chr4:42061189:G:A | - | 0.112277180336825 | 0.0429396491456461 | STAD | Female-baised eQTL |
| rs6447123 | chr4:42076224:A:G | - | 0.112277180336825 | 0.0429396491456461 | STAD | Female-baised eQTL |
| rs1036681 | chr4:47864945:G:A | - | -0.109055760188559 | 0.0498527116934974 | STAD | Female-baised eQTL |
| rs2033894 | chr4:47868537:G:A | - | -0.109055760188559 | 0.0498527116934974 | STAD | Female-baised eQTL |
| rs4365692 | chr4:47870620:A:G | - | -0.109055760188559 | 0.0498527116934974 | STAD | Female-baised eQTL |
| rs12647189 | chr4:47882203:A:G | - | -0.109055760188559 | 0.0498527116934974 | STAD | Female-baised eQTL |
| rs4695299 | chr4:47886640:T:A | - | -0.109055760188559 | 0.0498527116934974 | STAD | Female-baised eQTL |
| rs4694873 | chr4:47886641:G:T | - | -0.109055760188559 | 0.0498527116934974 | STAD | Female-baised eQTL |
| rs12499487 | chr4:36757759:A:G | - | 0.165204108353857 | 0.00107669278130906 | LUAD | Female-baised eQTL |
| rs62304188 | chr4:37408253:G:A | - | 0.126742740417945 | 0.00719351492084873 | LUAD | Female-baised eQTL |
| rs12501754 | chr4:36768862:C:T | - | 0.12812335062896 | 0.0121800173999735 | LUAD | Female-baised eQTL |
| rs1025678 | chr4:36785072:G:A | - | -0.114977185625227 | 0.0200328593684933 | LUAD | Female-baised eQTL |
| rs4832817 | chr4:36793912:C:T | - | 0.122615510636221 | 0.0307141502073224 | LUAD | Female-baised eQTL |
| rs4832815 | chr4:36787357:C:T | - | -0.115557908838175 | 0.0352092744156626 | LUAD | Female-baised eQTL |
| rs4832816 | chr4:36787652:A:C | - | -0.115557908838175 | 0.0352092744156626 | LUAD | Female-baised eQTL |
| rs9998115 | chr4:36791714:G:A | - | -0.115557908838175 | 0.0352092744156626 | LUAD | Female-baised eQTL |
| rs12648668 | chr4:36792171:C:T | - | -0.115557908838175 | 0.0352092744156626 | LUAD | Female-baised eQTL |
| rs1542016 | chr4:36794008:C:T | - | -0.115557908838175 | 0.0352092744156626 | LUAD | Female-baised eQTL |
| rs116694039 | chr4:42214908:C:T | - | 0.103472337336068 | 0.0365592762274614 | LUAD | Female-baised eQTL |
| rs13136954 | chr4:48437076:T:C | - | 0.0609383111810179 | 0.0459381657873616 | LUAD | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12650894 | chr4:47600582:T:G | - | 0.0585641331984645 | 0.0403060119905248 | KIRC | Male-baised eQTL |
| rs16861106 | chr4:48188348:A:G | - | 0.109606528503182 | 0.0102154270698575 | BLCA | Male-baised eQTL |
| rs16861108 | chr4:48190168:A:G | - | 0.109638691209901 | 0.011469065138849 | BLCA | Male-baised eQTL |
| rs35872281 | chr4:44298044:C:T | - | 0.0987185939610254 | 0.0144855376556325 | BLCA | Male-baised eQTL |
| rs2437321 | chr4:40762402:C:G | - | -0.0720812863458504 | 0.00285897453307946 | COAD | Male-baised eQTL |
| rs10938377 | chr4:44980436:G:A | - | 0.0627906477869734 | 0.00491059308671571 | COAD | Male-baised eQTL |
| rs10014926 | chr4:45012437:T:A | - | -0.106957314339672 | 0.0143750656188295 | COAD | Male-baised eQTL |
| rs28767592 | chr4:44867743:G:A | - | -0.0583220163165887 | 0.0298787315427825 | COAD | Male-baised eQTL |
| rs13110720 | chr4:44864880:C:G | - | -0.0539748823114338 | 0.0437019531111369 | COAD | Male-baised eQTL |
| rs10004766 | chr4:31455095:C:T | - | -0.0647687115205511 | 0.0475305658589959 | COAD | Male-baised eQTL |
| rs10016752 | chr4:31455101:T:A | - | -0.0647687115205511 | 0.0475305658589959 | COAD | Male-baised eQTL |
| rs10016758 | chr4:31455115:T:G | - | -0.0647687115205511 | 0.0475305658589959 | COAD | Male-baised eQTL |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg08016336 | chr4:41179301 | gene | -0.454148445613198 | 4.370165432943e-18 | -0.5935832771401027 | 1.5979411469960882e-20 | KIRP |
| cg15989892 | chr4:41061730 | gene | -0.217812337344524 | 6.42261946347858e-11 | -0.48262081827298203 | 4.008653915093562e-13 | KIRP |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| exon_skip_429274 | chr4:40935076:40935139 | In-frame | rs278986 | chr4:40492599:C:T | Distant downstream | -0.0748592941886122 | 0.0133093953623822 | PAAD | Female-baised sQTL |
| exon_skip_429274 | chr4:40935076:40935139 | In-frame | rs278984 | chr4:40492026:C:T | Distant downstream | -0.0746537380393873 | 0.0147548978210689 | PAAD | Female-baised sQTL |
| exon_skip_429274 | chr4:40935076:40935139 | In-frame | rs278985 | chr4:40492575:A:G | Distant downstream | -0.0727560850829631 | 0.0287226847154281 | PAAD | Female-baised sQTL |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| exon_skip_429286 | chr4:41065575:41065673 | 3UTR-3UTR | rs4860999 | chr4:41647700:G:C | Distant upstream | -0.0322927172503307 | 0.00630495267090968 | KIRC | Male-baised sQTL |
| exon_skip_429274 | chr4:40935076:40935139 | In-frame | rs12649306 | chr4:40945122:A:G | Distant upstream | -0.0727420697309343 | 0.00914020883663463 | KIRC | Male-baised sQTL |
| exon_skip_429274 | chr4:40935076:40935139 | In-frame | rs1983059 | chr4:40491563:A:G | Distant downstream | -0.0440022543961852 | 0.0490796253849791 | KIRC | Male-baised sQTL |
| exon_skip_429274 | chr4:40935076:40935139 | In-frame | rs794003 | chr4:40142179:G:T | Distant downstream | 0.0901818450222777 | 0.0455308902830988 | THCA | Male-baised sQTL |
| exon_skip_429274 | chr4:40935076:40935139 | In-frame | rs794002 | chr4:40142453:G:A | Distant downstream | 0.0901818450222777 | 0.0455308902830988 | THCA | Male-baised sQTL |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of APBB2 |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000163697 | APBB2 | C0043094 | Weight Gain | 1 | CTD_human |